{
  "docId": "019dd923-622c-750b-8b9a-2a2468219173",
  "docSlug": "ce565b841c40",
  "documentTitle": "Nevro Corp. (NVRO)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Kir Kahlon",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2021-01-07 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 218,
  "pageCount": 239,
  "prevPage": 217,
  "nextPage": 219,
  "slideType": "villain_critique",
  "function": "name_villain",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses inflammatory language ('cesspool', 'exploitation') to frame the company as a villain.",
  "elementsJson": [
    "headline_text",
    "paragraph",
    "photo",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-2a2468219173/218",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-2a2468219173#slide-218",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.24,
        "x": 0.71,
        "y": 0.52
      },
      "kind": "callout",
      "text": "Trial stimulator is externally secured and the procedure is not as invasive as a permanent surgical implant",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fff1d902-00fc-4e4a-806d-c497ade401d9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.42,
        "w": 0.65,
        "x": 0.05,
        "y": 0.52
      },
      "kind": "image",
      "text": null,
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fd488f15-968b-4a83-ae95-1c8f4d4d2fcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.9,
        "x": 0.05,
        "y": 0.13
      },
      "kind": "paragraph",
      "text": "A number of Nevro’s former executives, sales reps, and KOL’s described the exploitation of patients – particularly the psychiatrically vulnerable - as a key driver of the spinal cord stimulation business and of Nevro’s sales in particular, portraying it as a cesspool of unethical and illegal practices with troubling incentives driving corporate, sales rep, and doctor behavior. We detail five practices: 1) pushing unnecessary trial implants; 2) pushing permanent implants even if the trial implant indicated no pain relief; 3) gaming mandatory psychiatric evaluations; 4) “flipping” implants and pushing unnecessary “upgrades”; and 5) implanters pressuring patients into simulators by withholding pain medication and other widespread, disturbing tactics. We begin by explaining what “stimulator trials” are: insurers require patients to begin with a trial period of a few days to a week, where temporary leads are attached to an external battery/generator. If the trial stimulator indicates at least 50% pain relief, the patients undergoes a permanent implant that is placed inside their body.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19062c15-9385-428d-84c1-daa4f7f47700",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.85,
        "x": 0.05,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: https://www.reddit.com/r/ChronicPain/comments/78yt1a/started_the_spinal_cord_stimulator_trialfeeling_a/; https://nickfener.wordpress.com/2013/02/18/spinal-cord-stimulator-trial/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8c90ca40-3eab-41ef-b0e3-25371f0fba42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.09
      },
      "kind": "title",
      "text": "Over-utilization, unnecessary implants, and patient exploitation are key drivers of Nevro’s sales",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c459619-952e-49f9-ab48-5b777bb4fa02",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.05,
        "y": 0.04
      },
      "kind": "title",
      "text": "Scorpion Capital | Nevro (NYSE: NVRO)",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e7ee908-2c35-4e17-beeb-255572d4440c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "antagonist-introduction",
      "slug": null,
      "matchId": "454424f3-688a-44ae-a8e6-57682be1977b",
      "evidence": "The slide explicitly frames the company as a villain by detailing unethical practices and patient exploitation.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}